Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vigabatrin and epilepsy: lessons learned.

John M Wild1, Hyo-sook Ahn, Michel Baulac

  • 1Cardiff School of Optometry and Vision Sciences, Cardiff University, Cardiff, United Kingdom. wildjm@cf.ac.uk

Epilepsia
|July 20, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel epilepsy treatments in clinical development.

Epilepsy & behavior : E&B·2026
Same author

Antiseizure Medications that Did Not Reach the Epilepsy Market: An Assessment of Factors Contributing to Their Failed Clinical Development Over the Last Three Decades.

Drugs·2026
Same author

Evolution of the European Medicines Agency clinical guidelines for epilepsy drug development between 2010 and 2025: A comparative analysis by the ILAE Task Force on Regulatory Affairs.

Epilepsia·2026
Same author

Novel pharmacological therapies in development.

Current opinion in neurology·2026
Same author

Epilepsy, neuroinflammation and cannabidiol What do we know thus far?

Frontiers in pharmacology·2026
Same author

Transcription Factor Binding and Individual Genetic Risk of Valproate Teratogenicity.

Neurology·2026
Same journal

Psychological stress during wartime and its association with seizure-related emergency department utilization.

Epilepsia·2026
Same journal

WONOEP appraisal: Biomarkers and treatment strategies beyond the synapse.

Epilepsia·2026
Same journal

Does electrocorticographic guidance improve seizure outcomes following cavernoma resection?

Epilepsia·2026
Same journal

Raising resilience: A parenting intervention for families affected by childhood epilepsy.

Epilepsia·2026
Same journal

Epileptogenic lesions in the Australian epilepsy project: A harmonized 3-T magnetic resonance imaging protocol and its diagnostic yield.

Epilepsia·2026
Same journal

Responsible use of artificial intelligence in peer-reviewed publications in epilepsy.

Epilepsia·2026
See all related articles

Vigabatrin (VGB) therapy for epilepsy increases the risk of visual field loss (VAVFL) with longer exposure and higher doses. This risk progresses over time, impacting treatment decisions for patients with refractory epilepsy.

Area of Science:

  • Ophthalmology
  • Neurology
  • Pharmacology

Background:

  • Vigabatrin (VGB) is an antiepileptic drug used for refractory partial epilepsy.
  • The risk factors for VGB-associated visual field loss (VAVFL) require clarification.

Purpose of the Study:

  • To identify the primary risk factors contributing to VGB-associated visual field loss (VAVFL).
  • To analyze the relationship between VGB exposure, dosage, and the incidence of VAVFL.

Main Methods:

  • A multinational, prospective, observational study involving three groups of patients with refractory partial epilepsy.
  • Participants were stratified by age and VGB exposure: current users (Group I), previous users (Group II), and never users (Group III).
  • Perimetry was conducted regularly for up to 36 months, with masked evaluation of results.

Related Experiment Videos

Main Results:

  • VAVFL occurred in 31.2% (8-12 years) and 41.6% (>12 years) of current VGB users (Group I).
  • VAVFL was significantly associated with duration of VGB therapy (OR 14.2), mean VGB dose (OR 8.5), and male gender (OR 2.1).
  • Static perimetry detected VAVFL more frequently than kinetic perimetry (OR 2.3).

Conclusions:

  • The benefits of VGB are offset by a progressive increase in VAVFL risk with continued exposure and higher mean doses.
  • Monitoring visual fields is crucial for patients on long-term VGB therapy.
  • Understanding these risk factors can inform clinical management and patient counseling.